GFM
STOK icon

GF Fund Management’s Stoke Therapeutics STOK Stock Holding History

GF Fund Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41.8K Buy
1,283
+162
+14% +$5.31K ﹤0.01% 419
2025
Q4 		$35.6K Sell
1,121
-58
-5% -$1.74K ﹤0.01% 441
2025
Q3 		$27.7K Sell
1,179
-176
-13% -$3.02K ﹤0.01% 450
2025
Q2 		$15.4K Hold
1,355
– – ﹤0.01% 525
2025
Q1 		$9.01K Buy
1,355
+243
+22% +$2.27K ﹤0.01% 580
2024
Q4 		$12.3K Buy
+1,112
New +$13.7K ﹤0.01% 520

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

GF Fund Management's STOK Position: Q1 2026 in Review

GF Fund Management increased its Stoke Therapeutics (STOK) stake by 14% in Q1 2026, buying an estimated $5.31K and bringing the position to 1,283 shares worth $41.8K. The position accounts for ﹤0.01% of the portfolio, ranked #419.

GF Fund Management first reported a position in STOK in Q4 2024 and has held it in 6 quarters since. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • GF Fund Management held 1,283 shares of Stoke Therapeutics worth $41.8K as of Q1 2026.
  • GF Fund Management bought 162 Stoke Therapeutics shares in Q1 2026, an estimated $5.31K.
  • Stoke Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #419 holding.
  • GF Fund Management first reported a position in Stoke Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.